Study Atlas
Study accountPrivacySaved locally

Pediatrics

Wilson disease

Wilson disease brings together liver injury, movement or behavioral changes, and abnormal copper handling. Diagnose it using the whole pattern.

Very High Yield37 min lesson estimate44 question families

Well covered in the main question banks · 52 main-bank entries · 67 linked PDF entries · 0 generated drills

Prerequisites and related lessons
  • Non-viral hepatitis

Curriculum reference · Official College Textbook – Digestive Disorders – Part 2, pp. 122–125. Lesson adapted from Pediatric hepatology and metabolic disease.

Topic map

  • ATP7B on chromosome 13recessive copper disorder
  • Reduced biliary copper excretionhepatic, neurologic and ocular injury
  • Testsceruloplasmin, urine copper, slit lamp and genotype or liver copper
  • Treatlifelong copper control, family screening, transplant if severe

Scroll the diagram to see all labels.

ATP7B and copper accumulationCopper normally leaves hepatocytes via bile. With impaired ATP7B, copper accumulates and can injure extrahepatic tissues.HepatocyteCopper accumulates Bile excretionATP7B defect Circulating copperLess copper in ceruloplasminBrain, corneaKidney, red cells
ATP7B and copper accumulationCopper normally leaves hepatocytes via bile. With impaired ATP7B, copper accumulates and can injure extrahepatic tissues.

Genetics and pathogenesis

Wilson disease, or hepatolenticular degeneration, is an autosomal recessive ATP7B disorder on chromosome 13 [Pediatric Mid Q6/Q8/Q11 · Formative Q7 · Old]. ATP7B normally transfers copper into bile and helps incorporate it into apoceruloplasmin. Defective biliary copper excretion [Old p. 114 Q8] leads to hepatic accumulation and later spillover to the basal ganglia, cornea, kidneys and other tissues. Poor incorporation contributes to low circulating ceruloplasmin. Toxic non-ceruloplasmin-bound copper can damage cells. Total serum copper can be low despite tissue overload because much normal serum copper is carried by ceruloplasmin.

Clinical picture and complications

Think of it in school-age children and adolescents with unexplained transaminitis, fatty liver, hepatitis, cirrhosis, portal hypertension or acute liver failure. Clinical onset before age five is unusual [Pediatric Mid Q6 · Old]. The exam identifies the liver, brain and eyes as frequent sites. Kidney and skeleton can also be affected. Splenomegaly may result from portal hypertension and the spleen is not a classic primary deposit site. Lung disease is not characteristic.

Tremor, dysarthria, dystonia and parkinsonism [Pediatric Mid Q10/Q13 · IRAT case 1] reflect basal ganglia involvement. Clumsiness, poor school performance or psychiatric symptoms can precede recognition. Hemiplegia is the exam exception. Kayser–Fleischer rings [Pediatric Mid Q13 · IM Mid Q4 · Old] are green-brown copper deposits in Descemet membrane, best seen by slit lamp. They may be absent in younger patients with liver-only disease and can fade with treatment. Sunflower cataracts are a different, less common finding.

Wilson acute liver failure may produce Coombs-negative hemolysis [Old p. 80 Q34], renal dysfunction and relatively low ALP for the degree of hyperbilirubinemia. Free copper oxidatively damages red cells. Ratios can support suspicion but are imperfect in children, particularly because ALP varies with age. The IRAT case combines jaundice, ascites, declining school performance and tremor with ceruloplasmin 8 mg/dL, urine copper 180 μg/24 h and a positive slit lamp [IRAT case 1]. Decompensation with altered mental status merits urgent specialty and transplant-center assessment.

Diagnostic evidence

Initial assessment
Ceruloplasmin, 24-hour urine copper, slit lamp and liver assessments
Confirmation or next test
Combine clinical, biochemical and ATP7B evidence; quantitative hepatic copper if needed

Use liver profile, INR, CBC, hemolysis studies as indicated, low serum ceruloplasmin and increased 24-hour urinary copper [Pediatric Mid Q12–13 · IM Mid · Old], slit-lamp examination and ATP7B evaluation. Ceruloplasmin below about 20 mg/dL is a clue and very low values strengthen suspicion. Normal values do not exclude disease and low values occur in other contexts. Basal urinary copper >100 μg/24 h supports symptomatic disease; >40 μg/24 h can be meaningful in children or presymptomatic cases. Check collection quality and confounding cholestasis or severe liver injury.

Use combined evidence, such as the Leipzig score and disease-causing ATP7B variants. Quantitative hepatic copper by biopsy [Pediatric Mid Q13 · IM Mid Q1 · Old] is the recorded choice in “best confirmation/gold standard” questions. Values above roughly 250 μg/g dry weight support the diagnosis in context, with sampling variation and other cholestatic causes considered. It is not required in every patient with convincing clinical, biochemical and genetic evidence. The old penicillamine provocation test is a historical source convention rather than the routine diagnostic default.

Management and follow-up

Treatment is lifelong. D-penicillamine or trientine [Book II pp. 124–125 · IRAT case 1] chelates copper and increases urine excretion. Choose with specialist guidance according to hepatic/neurologic disease, tolerability and access. Pyridoxine (vitamin B6) [Pediatric Mid Q7 · Old] is typically supplemented with penicillamine. Follow CBC, renal function, urinalysis and treatment copper measures, with awareness of neurologic worsening or overtreatment. Zinc [Pediatric Mid Q6] decreases intestinal copper absorption via metallothionein induction and has roles in selected presymptomatic or maintenance settings. Significant symptomatic liver disease generally requires chelation and urgent severity assessment, rather than relying on zinc alone.

Diet is adjunctive. The course asks to limit dietary copper and identifies liver and chocolate [Pediatric Mid Q4/Q9 · Old], with some shellfish and nuts among copper-rich foods. Do not substitute dietary changes for medication. Screen siblings and other first-degree relatives using familial genotype and clinical/biochemical evaluation as appropriate. Consider liver transplantation [IRAT case 1 · Book II p. 124] for Wilson acute liver failure or severe decompensated disease. Avoid unplanned treatment interruption because severe relapse can occur.

Exam traps

A low ceruloplasmin is a clue, not isolated proof. High urine copper and corneal rings strengthen the combined diagnosis. “Gold standard” wording in the local exam usually points to quantitative liver copper among the options. In clinical work, combine noninvasive findings and genetics before assuming every patient needs biopsy.

Diagnostic and management pathways

  • Unexplained liver disease, movement signs or family history → liver/synthetic tests, ceruloplasmin, urine copper and slit lamp
  • Integrate ATP7B and Leipzig evidence → use hepatic copper when unresolved and safe
  • Hemolysis or rapid decompensation → urgent liver/transplant evaluation
  • Confirmed → lifelong specialist therapy, monitoring and family screening

Compare at a glance

FindingWhy it occursExam distinction
Low ceruloplasminPoor copper incorporation into carrier proteinA clue can coexist with low total serum copper
High urinary copperIncreased circulating non-ceruloplasmin-bound copperInterpret collection, age and other liver injury
Kayser–Fleischer ringCopper in Descemet membraneMay be absent in liver-only cases or fade after treatment
Coombs-negative hemolysisOxidative red-cell injury from free copperImportant severe hepatic clue
Chelator vs zincChelation raises copper excretion; zinc reduces absorptionSelect by disease severity and treatment phase

Supplementary clarification – not directly stated in the uploaded materials. Clinical references · EASL–ERN Wilson disease clinical practice guideline · AASLD Wilson disease executive summary

Exam words

  • autosomal recessive ATP7B disorder on chromosome 13 [Pediatric Mid Q6/Q8/Q11 · Formative Q7 · Old]
  • Defective biliary copper excretion [Old p. 114 Q8]
  • Clinical onset before age five is unusual [Pediatric Mid Q6 · Old]
  • Tremor, dysarthria, dystonia and parkinsonism [Pediatric Mid Q10/Q13 · IRAT case 1]
  • Kayser–Fleischer rings [Pediatric Mid Q13 · IM Mid Q4 · Old]
  • Coombs-negative hemolysis [Old p. 80 Q34]
  • ceruloplasmin 8 mg/dL, urine copper 180 μg/24 h and a positive slit lamp [IRAT case 1]
  • low serum ceruloplasmin and increased 24-hour urinary copper [Pediatric Mid Q12–13 · IM Mid · Old]
  • Quantitative hepatic copper by biopsy [Pediatric Mid Q13 · IM Mid Q1 · Old]
  • D-penicillamine or trientine [Book II pp. 124–125 · IRAT case 1]
  • Pyridoxine (vitamin B6) [Pediatric Mid Q7 · Old]
  • Zinc [Pediatric Mid Q6]
  • liver and chocolate [Pediatric Mid Q4/Q9 · Old]
  • liver transplantation [IRAT case 1 · Book II p. 124]

Practice questions

Rapid revision sheet

Sixty-second recall. Say the definition, the key clue and the next clinical step out loud before checking the list.

  • autosomal recessive ATP7B disorder on chromosome 13 [Pediatric Mid Q6/Q8/Q11 · Formative Q7 · Old]
  • Defective biliary copper excretion [Old p. 114 Q8]
  • Clinical onset before age five is unusual [Pediatric Mid Q6 · Old]
  • Tremor, dysarthria, dystonia and parkinsonism [Pediatric Mid Q10/Q13 · IRAT case 1]
  • Kayser–Fleischer rings [Pediatric Mid Q13 · IM Mid Q4 · Old]
  • Coombs-negative hemolysis [Old p. 80 Q34]

Official College Textbook – Digestive Disorders – Part 2, pp. 122–125

Active recall

Why can a child with a single normal ceruloplasmin result still require Wilson disease testing?

Ceruloplasmin alone is imperfect. Integrate clinical findings, urinary copper, eye examination and appropriate genetic or hepatic copper testing.

Official College Textbook – Digestive Disorders – Part 2, pp. 122–125

Recall the diagnostic and management pathway from memory.

Start with the presenting clue, name the first assessment, then distinguish confirmation, immediate management and follow-up.

  • Unexplained liver disease, movement signs or family history → liver/synthetic tests, ceruloplasmin, urine copper and slit lamp
  • Integrate ATP7B and Leipzig evidence → use hepatic copper when unresolved and safe
  • Hemolysis or rapid decompensation → urgent liver/transplant evaluation
  • Confirmed → lifelong specialist therapy, monitoring and family screening
↑